Compare
Acadia Pharmaceuticals vs Johnson & Johnson (ACAD vs JNJ)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Acadia Pharmaceuticals (ACAD) returned -4.9% and Johnson & Johnson (JNJ) +48.5%; so far this year the figures are -20.5% and +33.5%.
Johnson & Johnson is the larger company by market value, about 181.2 times the size of Acadia Pharmaceuticals.
On trailing earnings, ACAD trades at 10.0 times and JNJ at 41.9 times.
Revenue grew +14.8% at ACAD and +7.8% at JNJ over the last year.
ACAD pays no dividend. JNJ yields 1.91%.
Data as of the latest close. Not investment advice.
Relative performance
| ACAD | JNJ | |
|---|---|---|
| Price | $21.23 | $276.22 |
| 1-day | -0.05% | +1.43% |
| YTD | -20.52% | +33.47% |
| 1 year | -4.93% | +48.51% |
| 3 years | -7.37% | +85.77% |
| Market cap | $3.7B | $665.0B |
| P/E | 10.0 | 41.9 |
| P/S | 3.05 | 6.69 |
| P/B | 2.64 | 8.16 |
| Revenue growth | +14.80% | +7.80% |
| EPS growth | +36.80% | -36.40% |
| Gross margin % | 90.5 | 67.6 |
| Net margin % | 30.1 | 16.2 |
| ROE % | 26.1 | 19.7 |
| Debt / equity | 0.00 | 0.55 |
| FCF yield % | 2.2 | 3.1 |
| Dividend yield % | — | 1.91 |
| Beta | 0.66 | -0.09 |
| RSI (14) | 52.0 | 59.4 |
| Technical rating |